Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.

Hypertrophic Cardiomyopathy: Analyzing a Historical Series

75% of patients with hypertrophic Cardiomyopathy present symptoms. An important group responds very well to pharmacological treatment with betablockers and calcium antagonists, and those who do not respond, or do not tolerate these drugs, receive, at present, surgery as elective treatment. 

Miocardiopatía hipertrófica: análisis de una serie histórica

There is also alcohol septal ablation as an alternative strategy, which different studies have found favorable, even though its true benefit remains unclear, as well as the group of patients that would benefit from this treatment.  

The study looked at patients undergoing surgical septal myectomy and alcohol septal ablation (ASA) since 1998 to 2019 at the Mayo Clinic and the Fuwai Hospital. In all, it included 3274 patients undergoing septal myectomy and 585 ASA.

Primary end point was all cause mortality.

The ASA patients were older, had more hypertension, diabetes, kidney failure and heart disease, but had smaller septal thickness (19 mm vs 20 mm p=0.007) and no difference in gradient. 

At 30 days, mortality resulted similar: 0.7% vs 0.3% for ASA and septal myectomy respectively.

Read also: ACC 2022 | VALOR-HCM: Mavacamten in Adults with Symptomatic Obstructive HCM Eligible for Septal Reduction Therapy.

At 10 years, primary end point was higher in patients who had received ASA (26.1% vs. 8.2%), which was maintained after adjusting for variables such as age, sex and comorbidities (HR: 1.68; 95% CI: 1.29-2.19; P < 0.001).

Other parameters associated to mortality were functional class III-IV, obstructive pulmonary disease, stroke, atrial fibrillation, renal failures, diabetes and septal thickness, 

Conclusion

In patients with hypertrophic cardiomyopathy, alcohol septal ablation is associated with higher mortality in the long term, regardless other known factors, even though it might be affected by confounding factors overlooked as patient characteristics. 

Dr. Carlos Fava - Consejo Editorial SOLACI

Dr. Carlos Fava.
Member of the Editorial Board of SOLACI.org .

Original Title: Survival Following Alcohol Septal Ablation or Septal Myectomy for Patients With Obstructive. Hypertrophic Cardiomyopathy.

Reference: Hao Cui, et al. (J Am Coll Cardiol 2022;79:1647–1655).


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

EuroPCR 2026 | TAVI in Women: Do Supra-Annular Valves Offer a True Hemodynamic Advantage?

Women represent a particularly challenging population for TAVI, as they often have smaller aortic annuli, greater frailty, and an increased risk of prosthesis-patient mismatch....

EuroPCR 2026 | TAVI or Surgery in Younger Patients? Quality of Life and 3-Year Outcomes from NOTION-2

The expansion of TAVI into younger and lower surgical-risk populations has sparked a new debate: beyond mortality and stroke, which strategy provides better functional...

EuroPCR 2026 | MELA Registry: Myval Showed Lower Aortic Regurgitation Rates in Patients With Large Aortic Annuli

This presentation, delivered by Dr. Salvatore Giordano at EuroPCR 2026, detailed the results of the MELA Registry, a multicenter study comparing the performance of...

EuroPCR 2026 | LANDMARK Trial: Two-Year Results Showed Comparable Efficacy Between Myval and Contemporary TAVI Valves

The LANDMARK trial presentation, delivered by Prof. Patrick W. Serruys at EuroPCR 2026, detailed the two-year clinical outcomes of contemporary transcatheter aortic valve implantation...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

EuroPCR 2026 | TAVI in Women: Do Supra-Annular Valves Offer a True Hemodynamic Advantage?

Women represent a particularly challenging population for TAVI, as they often have smaller aortic annuli, greater frailty, and an increased risk of prosthesis-patient mismatch....

EuroPCR 2026 | TAVI or Surgery in Younger Patients? Quality of Life and 3-Year Outcomes from NOTION-2

The expansion of TAVI into younger and lower surgical-risk populations has sparked a new debate: beyond mortality and stroke, which strategy provides better functional...

EuroPCR 2026 | MELA Registry: Myval Showed Lower Aortic Regurgitation Rates in Patients With Large Aortic Annuli

This presentation, delivered by Dr. Salvatore Giordano at EuroPCR 2026, detailed the results of the MELA Registry, a multicenter study comparing the performance of...